Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
ORGANIZATION
New Industry Czar Vows to Balance Interests of Innovative Pharma, Gx Businesses as Budget Debate Creates Divide
Innovative pharma companies and generic makers often have clashing interests when it comes to debates on where to best allocate limited budgets, but the new chief of the FPMAJ - an umbrella organ of all drug trade groups in Japan…
To read the full story
Related Article
- JPMA Will Work towards Price Maintenance for On-Patent Medicines: New President
May 24, 2021
- Eisai’s Okada Elected as JPMA Chief, Daiichi Sankyo’s Manabe to Head FPMAJ
May 21, 2021
- Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues
January 7, 2021
- Daiichi Sankyo CEO Manabe Set to Gain Lobbying Experience as FPMAJ Vice Chair, Chairman Seat Eyed for 2021
June 10, 2020
- Daiichi Sankyo Chairman Nakayama to Step Aside as Adviser
May 12, 2020
- Japan Pharma Lobbies Hammer Out One-Year Term Extensions for Their Leaders
March 24, 2020
- Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
March 16, 2020
- Japan Pharma Lobbies Likely to Retain Chiefs as Off-Year Re-Pricing Debate Looms
February 21, 2020
ORGANIZATION
- Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025
- Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
- Wholesalers Urge Caution on Debating 2% Buffer without Bigger Reform Picture
November 28, 2025
- Labor Federation Files Request for 5% Drug Price Hike with Health Minister
November 28, 2025
- Japan PBSS Launches to Buttress Drug Discovery via Grassroots Networks
November 26, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…